Role of Leukotriene Receptor Antagonists in Treatment of Chronic Periodontitis

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The adjunctive use of Leukotriene Receptor Antagonist (Montelukast) along with scaling and root planing in patients with chronic periodontitis leads to host inflammatory response modulation and decrease in serum C reactive protein (CRP) levels. If proven this will open new vistas in treatment of chronic periodontitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tatyasaheb Kore Dental College
• Treatments: Leukotriene Antagonists; Montelukast

Criteria

Inclusion Criteria:

1. Patients within age group of 30 to 55 years.

2. Systemically healthy individuals.

3. Patients with chronic generalized periodontitis (moderate and severe) according to Center of Disease Control (CDC) working group, 2007 criteria

Exclusion Criteria:

1. Patients with systemic illnesses (i.e., diabetes mellitus, cancer, human immunodeficiency syndrome, bone metabolic diseases, or disorders that compromise wound healing, radiation, or immunosuppressive therapy),

2. Smoking,

3. Chronic alcoholics,

4. Pregnancy or lactation,

5. Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), steroids or antibiotics / antimicrobials within January 2012 to Jun 2013,

6. Confirmed or suspected intolerance to Montelukast,

7. Periodontal therapy done within the January 2012 to Jun 2013.